Δ9-tetrahydrocannabinol

Ligand id: 2424

Name: Δ9-tetrahydrocannabinol

Abbreviated name: THC

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: delta-9-tetrahydrocannabinol

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 0
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 29.46
Molecular weight 314.22
XLogP 6.21
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used in the treatment of anorexia in patients with AIDS, and treatment of nausea and vomiting associated with cancer chemotherapy in patients who have not reposnded to conventional antiemetic treatments. Clinical formulations of dronabinol are available in capsule form (Marinol®), and as of July 2016 (with US FDA apporval), as an oral solution (Syndros®).
Tetrahydrocannabinol, in a drug mixture containing cannabidiol (Sativex®, administered as an oromucosal spray), may also be used (in countries including the UK, Spain, Italy and Germany) to improve moderate to severe spastic symptoms in patients with multiple sclerosis (MS), and who have responded poorly to other anti-spasticity medications.
Mechanism Of Action and Pharmacodynamic Effects
The mechanism of action of THC is not completely understood. CB1 receptor agonist activity inhibits cyclic AMP production in areas of the central nervous system that mediate pain, memory, and other key functions, and is at least partially responsible for the physiological effects of cannabinoids. In addition, cannabidiol has been shown to stimulate vanilloid pain receptors (TRPVs), and to modulate cellular uptake and enzymatic hydrolysis of endogenous anandamide, effects which may contribute towards the pharmacological effects of cannabidiol [3].
External links